Full-Time

Vice President

Preclinical Development

Confirmed live in the last 24 hours

Metagenomi

Metagenomi

201-500 employees

Develops genome editing tools for therapeutics

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$280k - $360kAnnually

+ Equity + Bonuses

Senior, Expert

Oakland, CA, USA

This role is based at our Emeryville, California office.

Category
Computational Biology
Genomics
Biology & Biotech
Requirements
  • Ph.D. in Molecular Biology, Genetics, Biochemistry, or a related field; or an M.D. with significant laboratory research experience.
  • 15+ years in the biotech or pharmaceutical industry, ideally with expertise in gene editing, gene therapy, or novel therapeutic development, and a proven track record of advancing technologies from research through clinical development, including IND/CTA submissions.
  • Comprehensive experience in bioanalytical method development for translational research and deep knowledge of gene editing, molecular biology, and regulatory compliance.
  • Strategic leadership skills to bridge research insights with clinical applications.
  • Ability to inspire and engage diverse scientific teams, think strategically, and be a decisive problem-solver.
  • Excellent communication skills to effectively communicate complex scientific insights to stakeholders, including investors and regulatory bodies.
Responsibilities
  • Define and drive Metagenomi’s scientific vision, translating research discoveries into preclinical studies and advancing IND/CTA submissions.
  • Develop bioanalytical methods for preclinical and clinical studies, collaborating with bioanalytical teams to validate assays for gene editing efficacy, therapeutic transgene expression, and off-target analysis.
  • Lead data generation efforts for IND and CTA submissions, ensuring that translational research aligns with regulatory standards.
  • Build and inspire high-performing teams, fostering a collaborative environment that emphasizes scientific rigor, innovation, and continuous growth.
  • Build strategic alliances with academic and industry partners to strengthen Metagenomi’s translational research, representing the company at scientific conferences and industry forums.
  • Allocate resources efficiently to prioritize R&D programs with clear translational impact, manage program budgets, and ensure alignment with Metagenomi’s strategic priorities.

Metagenomi focuses on developing new genome editing tools for genetic medicine. The company explores natural environments to find undiscovered genetic material, which is then sequenced and engineered into potential therapeutics. By utilizing artificial intelligence and high-throughput screening, Metagenomi can quickly analyze billions of proteins to identify effective genome editing tools. This approach sets them apart from competitors who may not leverage such advanced technologies. The goal of Metagenomi is to create curative treatments for diseases through gene editing, aiming to significantly impact healthcare providers and patients.

Company Stage

IPO

Total Funding

$366.1M

Headquarters

Emeryville, California

Founded

2016

Growth & Insights
Headcount

6 month growth

-6%

1 year growth

-6%

2 year growth

51%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in metagenomics is driving investment in companies like Metagenomi.
  • AI in metagenomics allows faster discovery of novel genome editing systems.
  • Growing demand for personalized medicine boosts need for advanced genome editing tools.

What critics are saying

  • Class action lawsuit could damage Metagenomi's reputation and investor trust.
  • Termination of Moderna partnership may lead to financial instability for Metagenomi.
  • Significant stock price drop post-IPO suggests market skepticism about Metagenomi's model.

What makes Metagenomi unique

  • Metagenomi uses metagenomics and AI to discover novel genome editing systems.
  • The company sources genetic material from unexplored natural environments for unique discoveries.
  • Metagenomi's gene editing systems are ultra-small, efficient, and have reduced immune response risks.

Help us improve and share your feedback! Did you find this helpful?